Treatment of Trichomonas vaginalis in Women
Women with trichomoniasis should be treated with metronidazole 500 mg orally twice daily for 7 days, as this regimen has been shown to reduce treatment failure compared to single-dose therapy. 1
Recommended Treatment Regimen
The preferred treatment for women is:
- Metronidazole 500 mg orally twice daily for 7 days 1
This recommendation represents an important shift from older guidelines. While single-dose metronidazole 2 g was historically the primary recommendation 2, a randomized controlled trial demonstrated that the 7-day multidose regimen is superior in women, reducing repeat infection rates at test-of-cure from approximately 19% to 11% 1, 3.
Alternative Regimen
- Metronidazole 2 g orally as a single dose 2
- Tinidazole 2 g orally as a single dose (alternative nitroimidazole)
The single-dose regimen remains acceptable but is now considered second-line for women due to higher failure rates. It remains the preferred treatment for men 1.
Key Clinical Considerations
Partner Treatment is Essential
- All sexual partners must be treated simultaneously, even without testing 2, 4
- Patients should abstain from sexual intercourse until both partners complete therapy and are asymptomatic 2
- Partner treatment significantly increases cure rates beyond 90-95% 2
Test of Cure and Rescreening
- Routine test of cure is not necessary for asymptomatic patients after treatment 2
- Rescreening at 3 months is recommended due to high rates of reinfection 1
- Women with persistent symptoms should be re-evaluated
Treatment Failure Management
If initial treatment fails 2:
- First failure: Re-treat with metronidazole 500 mg twice daily for 7 days
- Repeated failure: Metronidazole 2 g orally once daily for 3-5 days
- Persistent failure: Consult infectious disease specialist; consider susceptibility testing and tinidazole therapy 5
Special Populations
Pregnancy
- After first trimester: Metronidazole 2 g single dose is recommended 4
- Treatment is warranted in symptomatic pregnant women to prevent adverse outcomes including preterm birth and premature rupture of membranes 6
- Metronidazole use in pregnancy has not shown consistent teratogenic effects 7
- First trimester: Older guidelines contraindicated metronidazole, but more recent evidence supports safety 2
HIV-Infected Women
- Use the same treatment regimens as HIV-negative women 2
- No dosage adjustment needed
Important Clinical Pitfalls
Topical Therapy is Ineffective
- Metronidazole gel is NOT recommended for trichomoniasis 2, 8
- Topical preparations achieve inadequate levels in the urethra and perivaginal glands, with efficacy <50% 8
- Only systemic oral therapy is appropriate
High-Risk Groups Requiring 7-Day Therapy
The multidose regimen is especially important for 3:
- Women with prior history of trichomoniasis (treatment failure rate 24.1% with single-dose vs 12.6% with multidose)
- Symptomatic women at baseline (21.4% vs 10.8% failure rates)
- These women should receive test of cure given high post-treatment infection rates
Metronidazole Resistance
- In vitro resistance remains relatively low at 4.3% 1
- Most resistant strains respond to higher doses or extended therapy 2
- Tinidazole may be effective when metronidazole fails 5
Practical Implementation
Recent data shows that implementing electronic health record alerts to promote the 7-day regimen over single-dose therapy significantly improves prescribing practices, with >60% acceptance rates among clinicians 9. This suggests the medical community is successfully transitioning to evidence-based multidose therapy for women.
The shift to 7-day therapy represents a meaningful improvement in cure rates and should be considered standard of care for women, reserving single-dose therapy for situations where adherence to multidose regimens is not feasible.